ClinicalTrials.gg
CompletedNCT05066035Updated Oct 4, 2021

Residual Paralysis and Reversal With Routine Neostigmine Versus Half-dose Sugammadex and Routine Neostigmine

A Phase 4 interventional study of Neostigmine and Sugammadex in Neuromuscular Blockade, Sugammadex and Neostigmine, sponsored by Kartal Kosuyolu Yuksek Ihtisas Education and Research Hospital. Completed. Open to participants aged 40 Years to 65 Years. Per ClinicalTrials.gov, last updated 2021-10-04.

Sponsored by Kartal Kosuyolu Yuksek Ihtisas Education and Research Hospital · Phase 4, Interventional, and Treatment

How we know

From the registry’s dates

  • Registered 8 years 4 months after the study started (first participant enrolled May 2013, registered Sep 2021).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
113
Allocation
Randomized
Ages
40 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 14 studies testing sugammadex in Delayed Emergence from Anesthesia — 2 open to participants now, 2 under way, none of them phase 3. Sugammadex · Delayed Emergence from Anesthesia.

Enrollment
5th of 14
113 · median 92
Started
2013
the only one that year
Phase 4
6 of 14
1 open now
Registered
9th of 14
by date
Lead sponsor
1 of 14
Kartal Kosuyolu Yuksek Ihtisas Education and Research Hospital

Among the 14 studies testing sugammadex in Delayed Emergence from Anesthesia, this one is the 5th largest by enrollment, is the only one that started in 2013, is one of 6 in phase 4, and was the 9th registered.

Delayed Emergence from Anesthesia

98 studies on the registry are indexed under Delayed Emergence from Anesthesia; 17 are open to participants now.

Browse Delayed Emergence from Anesthesia studies →

Open to participants now

2 of the 14 studies testing sugammadex in Delayed Emergence from Anesthesia are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

About sugammadex

Sugammadex: first FDA approval 2015 (BRIDION), first EMA approval 2008. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 8 Delayed Emergence from Anesthesia studies recruiting now, 2 set no upper age limit and 4 stop at 75 or younger; none take children under 18; 1 takes healthy volunteers.

This study: 40 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 14 studies testing sugammadex in Delayed Emergence from Anesthesia, or all of them as a file.
02

Study summary

Sugammadex may prevent residual neuromuscular blockade by providing rapid reversal at the end of the operation. Our goal is to compare the half-dose use of sugammadex for reversing residual blockade after administration of neostigmine and atropine to the routine use of reversal medication.

Read the detailed description

Background: Postoperative residual neuromuscular block (PONB) may be observed in patients in the recovery room after surgery, and this event causes significant adverse events such as respiratory muscle weakness, decreased tidal volumes causing hypoxemia, reintubation, prolonged mechanical ventilation, and possible risk for a cardiopulmonary arrest.

Goal: The study investigators hypothesized to investigate the effects of the half-dose use of sugammadex for reversing residual blockade after administration of neostigmine and atropine and compare these results to the routine full-dose use neostigmine and atropine.

The Study Design:

The study investigators planned to perform a prospective, single-blinded, randomized trial.

The study Protocol:

The investigators enrolled patients undergoing lower abdominal tumor resection surgery under general anesthesia who fulfill our inclusion criteria.

The study is single-blinded because the anesthesia resident, anesthesia technician, and anesthesia personnel, including the data collector, were blinded to the randomization. The supervising anesthesiologist was also a data collector, and she was not blinded to the study protocol.

The randomization into two groups required the use of a computer system. The study investigators performed a random allocation sequence by the use of randomized block design codes that are generated from a computer. Afterward, the study investigators opened an opaque and sealed envelope that contained the generated codes and randomly divided patients into two groups. During this process, they made sure that all study personnel was blinded to the randomization.

The study investigators divide patients into two groups after the randomization process, and the groups are as follows: The first group of 48 patients is called Group N. In this group of patients, and we administer intravenous neostigmine 0.05 mg/kg and atropine 0.02 mg/kg in a single syringe before extubation. The second group of 50 patients is called Group N+S. In Group N+S, the study investigators administered the standard reversal medications of intravenous neostigmine 0.05 mg/kg and atropine 0.02 mg/kg. Three minutes later, the study 'investigators administered an intravenous bolus dose of 1 mg/kg sugammadex in a different syringe prepared earlier as a reversal agent.

The Study Measurement of Parameters. The patients require general anesthesia induction with an intermediate-acting neuromuscular blocking age, rocuronium, at a dose of 0.06 mg/kg intravenously.

After induction of anesthesia and before administration of rocuronium, the investigators monitored train-of-four (TOF) counts using a monitoring device of neuromuscular blockade at the patient's ulnar nerve. For this purpose, they placed two surface electrodes above the ulnar nerve near the wrist. To monitor the nerve stimuli at the adductor pollicis muscle using acceleromyography (TOF Watch SX, Schering-Plough Ireland, Dublin, Ireland). After induction of general anesthesia, the TOF Watch device provided 50-Hz tetanic stimulation for 5 seconds, and one minute after this tetanic stimulation, it offered a train-of-four (TOF) stimulation. Depending on the TOF-watch-related parameters, they decided to administer rocuronium, the neuromuscular agent, or not. At the end of the surgery, all anesthetics needed to be discontinued, including inhalational agents who were sevoflurane and nitrous oxide. Once the end-tidal concentration of sevoflurane reached a 0.4-0.6% level, the investigators administered the previously randomized reversal study drug.

For the administration of the reversal agents, there was a need for a TOF count of 2 observed in the TOF Watch device. A TOF count of 2 in TOF Watch monitoring provided information of a shallow neuromuscular block.

The Collected Parameters. They observed the clinical signs of recovery using several parameters. These parameters are level of consciousness, head-lift test, ability to sustain head lift, general muscle weakness, laryngospasm, and desaturation.

The study investigators collected the periods between the last dose of intravenous rocuronium and administering a reversal agent, administering a reversal agent to extubation, and administering a reversal agent to operating room discharge. These periods were in minutes. They also collected the recovery periods between the start of helping reversal agent to the recovery of TOF ratio \< 0.9 to 0.7 and TOF ratio ≥ 0.9, which were in minutes.

They collected hemodynamical data, including; noninvasive mean arterial pressure, heart rate measurements, and peripheral oxygen saturation values before and subsequently at 2, 5, 10, and 30 minutes after administering the reversal drugs and in the recovery room.

The primary outcome was the incidence of a train-of-four (TOF) ratio less than 0.9 at tracheal extubation. The secondary outcomes were periods between the start of administering reversal agents and extubation or operating room discharge in minutes to achieve recovery of TOF ratio \< 0.9 to 0.7 and TOF ratio ≥ 0.9.

03

Conditions studied

  • Neuromuscular Blockade
  • Sugammadex
  • Neostigmine
  • Complication of Anesthesia
  • Postoperative Residual Curarization
  • Rocuronium

Keywords

  • Residual Curarization
  • Postoperative
  • Complication
  • Neuromuscular blockade
  • Neostigmine
  • Sugammadex
  • Rocuronium
04

Who can participate

Ages eligible
40 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Inclusion Criteria:

  • Inclusion criteria:
  • 40 and 65 years of age,
  • Physical Status (ASA-PS) of 3 and 4,
  • Elective lower gastrointestinal tumor resection surgeries,
  • Supine positioning,
  • Surgery requiring use of general anesthesia and muscle relaxation,
  • Use of inhalational agent of sevoflurane anesthesia,
  • Surgical duration of about three to six hours.

Exclusion Criteria:

  • History of known or suspected neuromuscular disease,
  • History of renal or hepatic dysfunction,
  • Hyperkalemia,
  • Patients receiving antibiotics, anticonvulsants, or magnesium,
  • History of stroke,
  • History of glaucoma,
  • History of pregnancy or breastfeeding,
  • Suspicion of abdominal infection or sepsis,
  • Suspected history of malignant hyperthermia,
  • An allergy to medications used during general anesthesia
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ASA physical status

The anaesthetists’ scale of health before surgery: I is healthy, II has a mild illness that is under control, III a severe one, IV a severe illness that is a constant threat to life. V and VI are used for the critically ill and for organ donors.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Outcomes assessor)
Enrollment
113 participants (actual)

Study arms

  • Active comparator
    Neostigmine

    The Group N (Neostigmine) (n=48), patients received standard intravenous neostigmine 0.05 mg/kg and atropine 0.02 mg/kg doses before extubation. A train-of-four (TOF) count of 2 in TOF Watch monitoring provides information of a shallow neuromuscular block. If at least two twitches are on the TOF watch monitor, the study investigators administer reversal medication for neuromuscular blockade in both groups. At this point, depending on randomization, a reversal agent is administered for each randomized group by an anesthesia resident or nurse who is blinded to the study protocol. The study investigators record the recovery periods between the start of administering the reversal agent to the recovery of TOF ratio \< 0.9 to 0.7 and TOF ratio ≥ 0.9 if it occurs. These time periods are in minutes.

    Drug: Neostigmine

  • Active comparator
    Neostigmine and Sugammadex

    In Group N+S (Neostigmine+Sugammadex) (n=50), patients received standard intravenous neostigmine 0.05 mg/kg and atropine 0.02 mg/kg doses before extubation. After a three-minute waiting period, the study investigators administered an intravenous bolus half-dose of 1 mg/kg of sugammadex after the standard reversal dose. A train-of-four (TOF) count of 2 in TOF Watch monitoring provides information of a shallow neuromuscular block. If at least two twitches are on the TOF watch monitor, the study investigators administer reversal medication for neuromuscular blockade in both groups. At this point, depending on randomization, a reversal agent is administered for each randomized group by an anesthesia resident or nurse who is blinded to the study protocol. The study investigators record the recovery periods between the start of administering the reversal agent to the recovery of TOF ratio \< 0.9 to 0.7 and TOF ratio ≥ 0.9 if it occurs. These time periods are in minutes.

    Drug: Sugammadex

Interventions

  • The study investigators administer neostigmine at the end of operation to reverse neuromuscular blockade, and the routine dose of the intravenous neostigmine is 0.05 mg/kg and atropine 0.02 mg/kg. The dose is given in a single syringe, and later they administer this reversal medication before extubation. In the case of a residual block, the neostigmine group of patients receives a rescue dose of neostigmine at a dose of 0.03 mg/kg in the operating room fifteen minutes before discharge.

    Also known as: Routine full-dose reversal medication

  • The study investigators administer the routine full-dose neostigmine reversal medication and three minutes later, they administer an intravenous bolus dose of 1 mg/kg sugammadex in a different syringe prepared earlier as a reversal agent. The anesthesia team considers using an intravenous rescue dose of 1 mg/kg sugammadex for this group of patients in the recovery room if patients do not show a complete recovery of TOF ratio equal to \>0.9 in the recovery room before discharge to the ward.

    Also known as: Routine full-dose reversal medication and half-dose sugammadex

06

What researchers measure

Primary outcomes

  1. Incidence of postoperative residual neuromuscular blockade (rNMB)

    Incidence of postoperative residual neuromuscular blockade (rNMB) (defined as a train-of-four ratio, TOFR \<0.9) measured 15 min after administration of the reversal agent.

    Time frame: After operation within 24 hours

  2. Recovery time-1

    The comparison of the recovery periods between groups when the start of administering reversal agent to the recovery of TOF ratio \< 0.9 to 0.7

    Time frame: After operation within 120 minutes

  3. Recovery time-2

    The comparison of the recovery periods between groups when the start of administering reversal agent to the recovery of TOF ratio \< 0.7

    Time frame: After operation within 120 minutes

  4. Recovery time-3

    The comparison of the recovery periods between groups when the start of administering reversal agent to the recovery of TOF ratio≥ 0.9

    Time frame: After operation within 24 hours

  5. Muscle strength after extubation

    The clinical assessment of muscle strength in the operating room are as follows; awake status, The investigated parameters were; arousable with minimal stimulation, cooperativeness, responsive only to tactile stimulation, cooperativeness, and able to perform five-second head lift.

    Time frame: After operation within 24 hours

Secondary outcomes

  1. Adverse events-1

    Adverse events related to administration of reversal medications

    Time frame: After operation within 24 hours

  2. Adverse events-2

    Adverse events related to residual paralysis

    Time frame: After operation within 24 hours

  3. Rescue medication neostigmine

    A rescue dose of intravenous neostigmine at a dose of 0.03 mg/kg in the operating room after 15 minutes before discharge to recovery room.

    Time frame: After operation within 120 minutes

  4. Rescue medication sugammadex

    A rescue dose of intravenous sugammadex at a dose of 1 mg/kg in the recovery room after 15 minutes before discharge to the ward from recovery room

    Time frame: After operation within 120 minutes

  5. Time frame-1

    The time period between the last dose of intravenous rocuronium and administering a reversal agent

    Time frame: After operation within 30 minutes

  6. Time frame-2

    The time period between administering a reversal agent to extubation

    Time frame: After operation within 30 minutes

  7. Time frame-3

    The time period between administering a reversal agent to operating room discharge

    Time frame: After operation within 60 minutes

  8. Time frame-4

    The time period between discharge from the operating room amd discharge from recovery room

    Time frame: After operation within 120 minutes

  9. Aldrete Score greater than nine in the recovery room

    The criteria for patient discharge from the recovery room

    Time frame: After operation within 120 minutes

Other outcomes

  1. Noninvasive mean arterial pressure

    Mean arterial blood pressure measurements during operation and after operation

    Time frame: During operation every 5 minutes and after operation in the recovery room every five minutes until discharge.

  2. Heart rate

    Heart rate measurements during operation and after operation

    Time frame: During operation every 5 minutes and after operation in the recovery room every five minutes until discharge.

  3. Peripheral oxygen saturation

    Peripheral oxygen saturation during operation and after operation

    Time frame: During operation every minute and after operation in the recovery room every minute until discharge.

07

Study locations

No study locations are listed for this record.

08

References and documents

Publications

  • Duvaldestin P, Kuizenga K, Saldien V, Claudius C, Servin F, Klein J, Debaene B, Heeringa M. A randomized, dose-response study of sugammadex given for the reversal of deep rocuronium- or vecuronium-induced neuromuscular blockade under sevoflurane anesthesia. Anesth Analg. 2010 Jan 1;110(1):74-82. doi: 10.1213/ANE.0b013e3181c3be3c. Epub 2009 Nov 21. PubMed 19933538 ↗
  • Puhringer FK, Gordon M, Demeyer I, Sparr HJ, Ingimarsson J, Klarin B, van Duijnhoven W, Heeringa M. Sugammadex rapidly reverses moderate rocuronium- or vecuronium-induced neuromuscular block during sevoflurane anaesthesia: a dose-response relationship. Br J Anaesth. 2010 Nov;105(5):610-9. doi: 10.1093/bja/aeq226. Epub 2010 Sep 28. PubMed 20876699 ↗
  • Aouad MT, Alfahel WS, Kaddoum RN, Siddik-Sayyid SM. Half dose sugammadex combined with neostigmine is non-inferior to full dose sugammadex for reversal of rocuronium-induced deep neuromuscular blockade: a cost-saving strategy. BMC Anesthesiol. 2017 Apr 11;17(1):57. doi: 10.1186/s12871-017-0348-9. PubMed 28399799 ↗
  • Schaller SJ, Fink H, Ulm K, Blobner M. Sugammadex and neostigmine dose-finding study for reversal of shallow residual neuromuscular block. Anesthesiology. 2010 Nov;113(5):1054-60. doi: 10.1097/ALN.0b013e3181f4182a. PubMed 20885293 ↗
  • Cheong SH, Ki S, Lee J, Lee JH, Kim MH, Hur D, Cho K, Lim SH, Lee KM, Kim YJ, Lee W. The combination of sugammadex and neostigmine can reduce the dosage of sugammadex during recovery from the moderate neuromuscular blockade. Korean J Anesthesiol. 2015 Dec;68(6):547-55. doi: 10.4097/kjae.2015.68.6.547. Epub 2015 Nov 25. PubMed 26634077 ↗

Individual participant data

Plan to share: Yes — We plan to share our data with individuals or organizations who reach us via phone, e-mail, or address.

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report, Analytic code

Time frame: In a month after the release of the registration at https://register.clinicaltrials.gov.

Access criteria: The study is under peer review at a journal, and after its publication, we are planning to share our data individually by responding to each request.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from May 2013 to primary completion in Oct 2016, 41 months.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 9, 2021
First posted
Oct 4, 2021
StartActual
May 1, 2013
Primary completionActual
Oct 1, 2016
CompletionActual
Dec 30, 2016
Last update
Oct 4, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 4, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05066035
Lead sponsor
Kartal Kosuyolu Yuksek Ihtisas Education and Research Hospital
Responsible party
Ayse Baysal (Associate Professor of Anesthesiology and Reanimation, Kartal Kosuyolu Yuksek Ihtisas Education and Research Hospital) — Principal investigator
First posted
Oct 4, 2021
Start date
May 1, 2013
Primary completion
Oct 1, 2016
Completion
Dec 30, 2016
Last update
Oct 4, 2021

Study contacts

Ayşe Baysal
principal investigator · Kartal Kosuyolu High Speciality Training and Research Hospital

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Neostigmine · Sugammadex

Start the discussion